Since our study reports a high proportion of G6PD deficiency in patients of vivax malaria, epidemiologic and genotypic characterization may determine the rationale for G6PD deficiency screening of malaria patients receiving primaquine therapy. Here, G6PD is linked to Plasmodium vivax malaria.